Advanced Triple-Action Injectable Antibiotic
Rouzel Pharma proudly announces the launch of ROCEF-ES 1.5 GM and ROCEF-ES 3 GM Injection, an advanced injectable formulation combining Ceftriaxone + Sulbactam + EDTA (CSE). This innovative combination is developed to address the growing challenge of antimicrobial resistance by enhancing the effectiveness of Ceftriaxone against difficult-to-treat bacterial infections.
Disclaimer: The information provided in this blog is for informational purposes only and should not be considered medical advice. Always consult your doctor or a qualified healthcare professional before using any medication.
What Makes ROCEF-ES Different?
One of the key differentiators of ROCEF-ES is the inclusion of EDTA (Disodium Edetate), a non-antibiotic resistance breaker.
Unlike antibiotics, EDTA does not possess intrinsic antibiotic activity. Instead, when combined with antibiotics, it helps overcome multiple bacterial resistance mechanisms and enhances antimicrobial effectiveness.
Key Benefits of EDTA
- Does not possess intrinsic antibiotic activity.
- Helps overcome multiple bacterial resistance mechanisms.
- Enhances the antimicrobial effectiveness of antibiotics.
- Supports improved activity against resistant bacterial pathogens.
CSE: Ceftriaxone + Sulbactam + EDTA
The powerful CSE combination expands the in vitro activity of Ceftriaxone against bacteria producing multiple β-lactamases, including:
Class A β-lactamases
Class B β-lactamases
Class D β-lactamases
This broader resistance coverage makes ROCEF-ES an important advancement in injectable antimicrobial therapy.
Targets Multiple Resistance Mechanisms
ROCEF-ES demonstrates activity against several important bacterial defence systems responsible for antimicrobial resistance, including:
Efflux pump-mediated resistance
Bacterial biofilm formation
Altered membrane permeability
Horizontal gene transfer through conjugation
By targeting multiple resistance mechanisms simultaneously, ROCEF-ES enhances the clinical effectiveness of Ceftriaxone.
Preclinical Safety & Efficacy
Preclinical studies have demonstrated encouraging efficacy and an excellent safety profile for the CSE combination.
Highlights
Demonstrated efficacy in Klebsiella pneumoniae lung infection models.
Excellent safety profile observed in preclinical studies.
No significant toxicity noted even at 4.2 g/kg body weight in animal studies.
Provides an approximate 7-fold safety margin over the currently recommended clinical dose.
These findings support the safety and effectiveness of the CSE formulation before clinical application.
Clinical Validation & Regulatory Approval
The Ceftriaxone + Sulbactam + EDTA (CSE) combination has been clinically evaluated and approved in India.
Clinical Highlights
Approved in India based on successful Phase III Clinical Trials.
Clinical Trial Registration: CTRI/2010/09/000174
Evaluated for safety and efficacy across multiple bacterial infections, including Complicated Urinary Tract Infections (cUTIs).
Demonstrated superior clinical outcomes compared with Ceftriaxone alone.
These clinical findings reinforce the role of ROCEF-ES as an advanced injectable antibiotic formulation for resistant bacterial infections.
Why Choose ROCEF-ES?
ROCEF-ES combines the proven antibacterial efficacy of Ceftriaxone, the β-lactamase inhibition of Sulbactam, and the resistance-breaking properties of EDTA into one innovative injectable formulation.
Advantages of ROCEF-ES
- Advanced Triple-Action Formula
- Broad β-lactamase coverage
- Targets multiple bacterial resistance mechanisms
- Enhanced antimicrobial efficacy
- Excellent preclinical safety profile
- Clinically validated in India
- Suitable for managing difficult-to-treat bacterial infections
Conclusion
With the launch of ROCEF-ES 1.5 GM and ROCEF-ES 3 GM Injection, Rouzel Pharma strengthens its commitment to delivering innovative healthcare solutions.
The unique Ceftriaxone + Sulbactam + EDTA (CSE) formulation combines proven safety with advanced resistance-breaking capabilities, offering enhanced antimicrobial efficacy against difficult-to-treat bacterial infections. ROCEF-ES represents a significant step forward in supporting clinicians with effective treatment options in the fight against antimicrobial resistance.
Contact Us Today
📞 Phone: +91 9592087880
📧 Email: rouzelpharmapl@gmail.com
🌐 Website: www.rouzelpharma.in
You May Also Like : https://rouzelpharma.in/2026/06/23/complete-nutrition-starts-here-explore-rouzel-pharmas-protein-powder-portfolio/
